| 9.93 -0.02 (-0.2%) | 12-05 10:10 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.34 | 1-year : | 14.41 |
| Resists | First : | 10.56 | Second : | 12.34 |
| Pivot price | 9.74 |
|||
| Supports | First : | 9.36 | Second : | 8.61 |
| MAs | MA(5) : | 9.84 |
MA(20) : | 9.6 |
| MA(100) : | 8.09 |
MA(250) : | 0 | |
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 49.8 |
D(3) : | 48.6 |
| RSI | RSI(14): 66.2 |
|||
| 52-week | High : | 10.56 | Low : | 5.51 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ FOLD ] has closed below upper band by 19.4%. Bollinger Bands are 19.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.01 - 10.05 | 10.05 - 10.1 |
| Low: | 9.51 - 9.57 | 9.57 - 9.62 |
| Close: | 9.86 - 9.95 | 9.95 - 10.03 |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Fri, 05 Dec 2025
Schroder Investment Management Group Purchases 649,177 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Thu, 04 Dec 2025
Amicus Therapeutics (NASDAQ:FOLD) CEO Sells 14,587 Shares - MarketBeat
Thu, 04 Dec 2025
Amicus Therapeutics (FOLD) Up 6.4% Since Last Earnings Report: Can It Continue? - Nasdaq
Tue, 02 Dec 2025
Capital Fund Management S.A. Has $4.37 Million Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Mon, 01 Dec 2025
Amicus Therapeutics, Inc. $FOLD Stock Position Raised by Virtus Investment Advisers LLC - MarketBeat
Sun, 30 Nov 2025
Creative Planning Purchases 180,652 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 309 (M) |
| Shares Float | 306 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 103.5 (%) |
| Shares Short | 18,040 (K) |
| Shares Short P.Month | 18,950 (K) |
| EPS | -0.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.75 |
| Profit Margin | -2.4 % |
| Operating Margin | 20.2 % |
| Return on Assets (ttm) | 2.6 % |
| Return on Equity (ttm) | -6.9 % |
| Qtrly Rev. Growth | 19.5 % |
| Gross Profit (p.s.) | 1.74 |
| Sales Per Share | 1.94 |
| EBITDA (p.s.) | 0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 13 (M) |
| Levered Free Cash Flow | 38 (M) |
| PE Ratio | -249.63 |
| PEG Ratio | 0 |
| Price to Book value | 13.31 |
| Price to Sales | 5.14 |
| Price to Cash Flow | 237.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|